Difference between revisions of "Team:Queens Canada/Circ AFP"
(6 intermediate revisions by the same user not shown) | |||
Line 47: | Line 47: | ||
</div> | </div> | ||
− | <div class="intro" style="padding: | + | <div class="intro" style="padding: 60px 200px 20px 200px;"> |
− | <h1> | + | <h1>ICEFINITY: CIRCULARIZED AFP</h1> |
− | <p>Inteins have been proven to be an efficient way to circularize proteins<sup>1</sup>. Furthermore, studies have shown that joining the termini of proteins leads to a significant increase in their thermo-stability<sup>2, 3</sup>. In 2014, The Heidelberg iGEM team worked on generating BioBricks which allow for this circularization. This year, our Icefinity project sought out to stabilize the Type III antifreeze protein (AFP) using their methods, specifically utilizing the Npu dnaE split intein found in part BBa_K1362000</p> | + | <p>Inteins have been proven to be an efficient way to circularize proteins<sup>1</sup>. Furthermore, studies have shown that joining the termini of proteins leads to a significant increase in their thermo-stability<sup>2, 3</sup>. In 2014, The Heidelberg iGEM team worked on generating BioBricks which allow for this circularization. This year, our Icefinity project sought out to stabilize the Type III antifreeze protein (AFP) using their methods, specifically utilizing the Npu dnaE split intein found in part BBa_K1362000.</p> |
</div> | </div> | ||
Line 57: | Line 57: | ||
<h2>Design & Cloning</h2> | <h2>Design & Cloning</h2> | ||
− | <p>A thorough dry lab analysis was performed to determine the appropriate linker needed to circularize the AFP. Details about this crucial dry lab stage are described on our Modeling Page | + | <p>A thorough dry lab analysis was performed to determine the appropriate linker needed to circularize the AFP. Details about this crucial dry lab stage are described on our <a href="https://2015.igem.org/Team:Queens_Canada/Modeling">Modeling Page</a>. After selecting the optimal linker (GAA), The AFP-linker-extein insert sequence was then designed to be compatible with the Golden Gate Assembly technique necessary for BBa_K1362000; BsaI cut sites were placed on the ends of the insert sequence to allow for successful insertion into Heidelberg’s BioBrick. The final designed insert is illustrated below in Figure 1.</p> |
<figure style="width:400px; float: right;"> | <figure style="width:400px; float: right;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/d/dc/Qqq_QGEM_BBa_K1831000.png" style="width:400px; float: right;"/> |
<figcaption>Figure 1. <strong>Designed construct of BBa_; our circular AFP. </strong></figcaption> | <figcaption>Figure 1. <strong>Designed construct of BBa_; our circular AFP. </strong></figcaption> | ||
</figure> | </figure> | ||
Line 66: | Line 66: | ||
<p>The cloning of our circAFP began with a Golden Gate Assembly Reaction, the insert being our AFP-linker-extein sequence described above. Golden Gate Assembly involved a one-pot reaction, where both insert and vector were cut then ligated to generate a pSB1C3 plasmid containing our gene of interest. The Golden Gate Assembly Reaction was then transformed onto Topten electro-competent E. coli cells and plated onto Chloramphenicol-resistant plates. Successful cloning was determined by colony growth and colour (Heidelberg’s part contained an RFP; therefore, non-red colonies would indicate successful gene insertion). Colonies were picked and screened for our gene of interest. Next, our gene of interest was then inserted into a plasmid containing a T7 promoter and ribosomal-binding site to be used for protein expression. To determine successful insertion, further colony screening was performed (Figure 2).</p> | <p>The cloning of our circAFP began with a Golden Gate Assembly Reaction, the insert being our AFP-linker-extein sequence described above. Golden Gate Assembly involved a one-pot reaction, where both insert and vector were cut then ligated to generate a pSB1C3 plasmid containing our gene of interest. The Golden Gate Assembly Reaction was then transformed onto Topten electro-competent E. coli cells and plated onto Chloramphenicol-resistant plates. Successful cloning was determined by colony growth and colour (Heidelberg’s part contained an RFP; therefore, non-red colonies would indicate successful gene insertion). Colonies were picked and screened for our gene of interest. Next, our gene of interest was then inserted into a plasmid containing a T7 promoter and ribosomal-binding site to be used for protein expression. To determine successful insertion, further colony screening was performed (Figure 2).</p> | ||
<figure style="width:600px; display: block; margin-left: auto; margin-right: auto;"> | <figure style="width:600px; display: block; margin-left: auto; margin-right: auto;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/7/79/Qqq_QGEM_colonyscreens.png" style="width: 600px;"/> |
<figcaption style="margin-left: 30px;">Figure 2. <strong>Agarose gel depicting screened colonies containing AFP-linker-extein within our vector containing a T7 promoter. </strong>Specifically, colonies 1 and 3-6 all appear to contain an insert of the correct size (about 800bp). Those select colonies were sequenced then used for subsequent transformation and protein expression.</figcaption> | <figcaption style="margin-left: 30px;">Figure 2. <strong>Agarose gel depicting screened colonies containing AFP-linker-extein within our vector containing a T7 promoter. </strong>Specifically, colonies 1 and 3-6 all appear to contain an insert of the correct size (about 800bp). Those select colonies were sequenced then used for subsequent transformation and protein expression.</figcaption> | ||
Line 79: | Line 79: | ||
<figure style="width:600px; display: block; margin-left: auto; margin-right: auto;"> | <figure style="width:600px; display: block; margin-left: auto; margin-right: auto;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/8/80/Qqq_QGM_circAFPexpression.png" style="width:600px; display: block; margin-left: auto; margin-right: auto;"> |
<figcaption style="margin-left: 30px;">Figure 3. <strong>SDS-PAGE of unpurified cell lysate components for both wild-type (WT) and circular AFP: supernatant (sup), pellet, and total cell lysate (TCL). </strong>First three columns show the WT AFP, and last three columns show the circAFP. Although the circAFP contains several additional amino acids, it appears to have run further down the gel. Similar results were visualized by the Heidelberg iGEM team in 2014. Cyclized proteins run further than their linear counterparts because of their more compact shape; this allows for the protein to travel through the gel much faster. </figcaption> | <figcaption style="margin-left: 30px;">Figure 3. <strong>SDS-PAGE of unpurified cell lysate components for both wild-type (WT) and circular AFP: supernatant (sup), pellet, and total cell lysate (TCL). </strong>First three columns show the WT AFP, and last three columns show the circAFP. Although the circAFP contains several additional amino acids, it appears to have run further down the gel. Similar results were visualized by the Heidelberg iGEM team in 2014. Cyclized proteins run further than their linear counterparts because of their more compact shape; this allows for the protein to travel through the gel much faster. </figcaption> | ||
Line 87: | Line 87: | ||
<figure style="width: 400px; float: left; margin-top: 50px;"> | <figure style="width: 400px; float: left; margin-top: 50px;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/9/9d/Qqq_QGEM_rightcircAFPse.png" style="width: 400px;" /> |
<figcaption>Figure 4. <strong>SDS-PAGE of the size exclusion column fractions, depicting the purified circAFP (Fraction A9).</strong> </figcaption> | <figcaption>Figure 4. <strong>SDS-PAGE of the size exclusion column fractions, depicting the purified circAFP (Fraction A9).</strong> </figcaption> | ||
</figure> | </figure> | ||
<figure style="width: 350px; float: right; "> | <figure style="width: 350px; float: right; "> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/2/23/Qqq_QGEM_AFPIAP.png" style="width: 260px;"/> |
<figcaption>Figure 5. <strong>SDS-PAGE of ice-affinity purified circAFP</strong>. This gel illustrate the results of one round of IAP. The single band in the last lane indicates the purified circAFP, isolated in the ice fraction. The liquid fraction represents all compounds not incorporated into the ice. </figcaption> | <figcaption>Figure 5. <strong>SDS-PAGE of ice-affinity purified circAFP</strong>. This gel illustrate the results of one round of IAP. The single band in the last lane indicates the purified circAFP, isolated in the ice fraction. The liquid fraction represents all compounds not incorporated into the ice. </figcaption> | ||
</figure> | </figure> | ||
Line 101: | Line 101: | ||
<figure style="float: right; width: 500px;"> | <figure style="float: right; width: 500px;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/b/ba/Qqq_QGEM_thgraph.png" style="float: right; width: 500px;"/> |
<figcaption>Figure 6. <strong>Bar graph of TH assay results, comparing wtAFP with our circAFP at various activity test conditions. </strong>Data shows that circAFP retains almost 80% of its antifreeze activity after being subjected to 90 <sup>o</sup>C . The wild-type AFP quickly loses its activity after exposure to such high temperatures. </figcaption> | <figcaption>Figure 6. <strong>Bar graph of TH assay results, comparing wtAFP with our circAFP at various activity test conditions. </strong>Data shows that circAFP retains almost 80% of its antifreeze activity after being subjected to 90 <sup>o</sup>C . The wild-type AFP quickly loses its activity after exposure to such high temperatures. </figcaption> | ||
</figure> | </figure> | ||
Line 108: | Line 108: | ||
<p style="margin-top: 20px;">To test circAFP’s thermostability, we treated three samples at three temperatures 37, 68, and 90 <sup>o</sup>C for 10 minutes each. Wild type samples were also treated at these same conditions. After treatment, TH assays were performed and TH gaps were compared based on percent retention of activity, relative to the untreated sample. Figure 6 shows a bar graph which illustrates these results. </p> | <p style="margin-top: 20px;">To test circAFP’s thermostability, we treated three samples at three temperatures 37, 68, and 90 <sup>o</sup>C for 10 minutes each. Wild type samples were also treated at these same conditions. After treatment, TH assays were performed and TH gaps were compared based on percent retention of activity, relative to the untreated sample. Figure 6 shows a bar graph which illustrates these results. </p> | ||
+ | |||
+ | <h1>References</h1> | ||
+ | <p>1. Scott, C.P. et al. (1999). “Production of cyclic peptides and proteins in vivo”. Proc. Natl. Acad. Sci. USA 96:13638–13643.</p> | ||
+ | <p>2. Iwai, H. and Pluckthun, A. (1999). “Circular beta-lactamase: stability enhancement by cyclizing the backbone”. FEBS 459:166-172.</p> | ||
+ | <p>3. Jeffries, C.M. et al. (2006). “Stabilization of a binary protein complex by intein-mediated cyclization”. Protein Science 15:2612–2618.</p> | ||
+ | <p>4. Zettler, J et al. (2009). “The naturally split Npu DnaE intein exhibits an extraordinarily high rate | ||
+ | in the protein trans-splicing reaction”. FEBS 583:909-914.</p> | ||
</div> | </div> |
Latest revision as of 00:10, 18 September 2015